Clinical trials: Small Intestine Cancer
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung
Open-Label Surufatinib in European Patients With NET
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
- Conditions
- Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
- Trial name
- NCT04579679
- Testing
- Surufatinib
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 78 people
- Sponsor
- Hutchmed
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences